The Predictive role of omentin-1, visfatin and adiponectin in osteoporosis-associated bone loss in postmenopausal women: a prospective cohort study

Background: There is conflicting evidence regarding adipocytokines in relation to bone mineral density (BMD) and osteoporotic fractures in women and men. Recently, we found that circulating omentin-1 levels had an inverse correlation with BMD at the lumbar spine in postmenopausal women. The main aim of this study was to investigate the predictive role of adipocytokines for bone loss and incident osteoporosis among postmenopausal women after a 5.8- year follow-up. Material and methods: A total of 382 healthy postmenopausal women who participated in a prospective cohort study were followed for 5.8 years. Omentin-1, visfatin, adiponectin, and the receptor activator of nuclear factor-κB ligand (RANKL) were measured by highly specific enzyme-linked immunosorbent assay methods. BMD was determined for the lumbar spine (L2–L4) and the proximal femur using dual-energy X-ray absorptiometry. Results: The femoral neck and lumbar spine bone loss at the 5.8-year follow-up were 1.0% and 3.4% per year.In logistic regression analysis, none of the studied adipocytokines predicted BMD at any skeletal sites or incident osteoporosis at the femoral neck or lumbar area after 5.8 year follow-up. However, RANKL levels predicted BMD at the lumbar spine (β=−0.19, p=0.003) and femoral neck (β=-0.341, p=0.018) after controlling for body mass index. Conclusion: Serum levels of omentin-1, visfatin and adiponectin did not predict bone loss and incident osteoporosis among postmenopausal women